• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

    24.73 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Denali Therapeutics Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Denali Therapeutics Q2 Earnings Call Highlights ↗
    Denali Therapeutics (NASDAQ:DNLI) reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded... 
    Via MarketBeat
    Topics Earnings
    Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates ↗
    Via Chartmill
    News headline image
    Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
    This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval ↗
    Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and... 
    Via MarketBeat
    News headline image
    Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval ↗
    This biotech company develops therapies for neurodegenerative and rare diseases, supported by clinical assets and pharma collaborations. 
    Via The Motley Fool
    Topics Regulatory Compliance
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
    On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
    Via Finterra
    Topics Economy Initial Public Offering
    News headline image
    Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
    Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More ↗
    Via The Motley Fool
    News headline image
    Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
    From Denali Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
    From Royalty Pharma plc
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.